Showing 1 - 10 of 55
The topic of innovation as a source of competitive advantage for firms is consolidated in the literature. An innovation-based advantage is generally achieved by following a structured process, in which technological capability plays a key role. However, a question remains in studies into...
Persistent link: https://www.econbiz.de/10011859340
We investigate optimal rewards in an R&D model where substitute ideas for innovation arrive to random recipients at random times. By foregoing investment in a current idea, society as a whole preserves an option to invest in a better idea for the same market niche, but with delay. Because...
Persistent link: https://www.econbiz.de/10013134773
Patent pools have become a prominent mechanism to reduce litigation risks and facilitate the commercialization of new technologies. This paper takes advantage of a window of regulatory tolerance under the New Deal to investigate the effects of pools that would form in the absence of effective...
Persistent link: https://www.econbiz.de/10013067064
At the beginning of 2014, the European Parliament and the Council adopted the new directive on public procurement. Inter alia, the new Directive introduces a new procedure called the innovation partnership. The availability of the new provisions maybe valuable particularly from the perspective...
Persistent link: https://www.econbiz.de/10012963930
The Medical Innovation Bill continues its journey through Parliament. On 23 January 2015, it was debated for the final time in the House of Lords and with one final amendment, the House moved to support the Bill, which then moved to the House of Commons on 26 January. It will be debated again on...
Persistent link: https://www.econbiz.de/10012911326
Persistent link: https://www.econbiz.de/10012935671
Persistent link: https://www.econbiz.de/10012826391
The National Institutes of Health (NIH) are responsible for the largest proportion of biological science funding in the United States. To protect the public interest in access to publicly funded scientific research, the NIH amended terms and conditions in funding agreements after 2009, requiring...
Persistent link: https://www.econbiz.de/10012971947
A number of antitrust cases have challenged firm conduct associated with the introduction of a new product. Several are in the pharmaceutical industry and have earned the moniker of “product hopping.” Other cases involve the design of interfaces that defeat interoperability and the supply of...
Persistent link: https://www.econbiz.de/10013001957